493 results
Search Results
2. Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations: Incorporating Resource Constraints in Health Economic Evaluations
3. Introducing Open Science in Teaching Health Economic Modelling
4. Working with Patients and Members of the Public: Informing Health Economics in Child Health Research
5. Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model
6. Identification and prioritisation of items for a draft participant-reported questionnaire to measure use of social care, informal care, aids and adaptations
7. Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom
8. Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review
9. Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
10. An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study
11. Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
12. Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines
13. A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers
14. Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands
15. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
16. Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation
17. Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease
18. Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
19. Clinical Complications and Healthcare Resource Utilization Associated with Conventional Management of Sickle Cell Disease with Recurrent Vaso-occlusive Crises and Transfusion-Dependent β-Thalassemia in Germany: Complications and HCRU of SCD with Recurrent VOCs and TDT
20. What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency: What Does Pharmaceutical 3D Printing Cost
21. Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium: Economic Impact of Reduced Insulin Pen Needle Reuse
22. Comparing Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patients’ Characteristics, Unmet Needs, and the Impact on Quality of Life and Costs in Germany: Collaborative Dementia Care Management in Different Settings
23. Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data: Cost-Effectiveness of NIVO+IPI for NSCLC Using Mixture-Cure Survival Analysis
24. Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India: Economic Evaluation for Knee Osteoarthritis Management in India
25. The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey
26. Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis
27. Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis
28. Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review: Economic Burden of Haemophilia from a Societal Perspective
29. From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment
30. CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks
31. Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment
32. Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial
33. Clinicians’ Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment
34. Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK
35. The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System
36. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
37. Economic Impact of Bladder Cancer in the USA
38. A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life
39. Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico
40. Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off
41. Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
42. Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
43. Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
44. Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians
45. Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance Schemes
46. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study
47. Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls
48. Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
49. Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications
50. Community Distribution of Naloxone: A Systematic Review of Economic Evaluations
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.